Contribution of metformin therapy with extended release formulas
Authors:
Andrej Dukát; Juraj Payer; Milan Kriška; Ján Gajdošík; Fedor Šimko
Authors‘ workplace:
V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava
1; Ústav farmakológie a lekárskej farmakológie LF UK v Bratislave
2; Neštátna ambulancia pre dospelých v Nových Zámkoch
3; Ústav patologickej fyziológie LF UK v Bratislave
4
Published in:
Forum Diab 2021; 10(1): 25-27
Category:
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
-
All articles in this issue
- Osteoporosis in endocrinopathies
- Assessment of the osteoporosis risk in patients with type 2 diabetes mellitus – when bone mineral density measurement is not sufficient
- Osteoporosis management in diabetic patient
- Contribution of metformin therapy with extended release formulas
- De-intensification of treatment in patient with diabetes mellitus could be beneficial
- Population differences in the prevalence of diabetes mellitus, its risk factors and complications
- Second generation basal insulin analogues in clinical trials using continuous monitoring of glucose levels
- Practical experience confirms the results of the RCT and RWE studies with empagliflosin: case reports
- Diabetic macular oedema treatment with intravitreal dexamethasone: case report
- Forum Diabetologicum
- Journal archive
- Current issue
- About the journal
Most read in this issue
- Osteoporosis in endocrinopathies
- Second generation basal insulin analogues in clinical trials using continuous monitoring of glucose levels
- De-intensification of treatment in patient with diabetes mellitus could be beneficial
- Population differences in the prevalence of diabetes mellitus, its risk factors and complications